Cannabis in obsessive-compulsive disorder

TL;DR

• Kayser 2020 (n=14): acute THC 7.5 mg → transient Y-BOCS ↓.
• Positive case reports with CBD 25–600 mg, no RCTs.
• First line remains SSRIs + exposure and response prevention (ERP).

Why evidence is thin

Cannabinoid OCD research has small samples, short follow-up and no replication. Cross-talk between the ECS and serotonergic 5-HT1A pathways is plausible but clinically unproven.

Neurobiological mechanisms and the endocannabinoid system

Neurobiological research suggests that the endocannabinoid system plays a regulatory role in the cortico-striato-thalamo-cortical circuits. These neural pathways are demonstrably hyperactive in patients with obsessive-compulsive disorder. Since CB1 receptors occur in high density in these brain regions, particularly in the striatum and prefrontal cortex, exogenous cannabinoids could theoretically have a modulating effect on synaptic transmission. Scientific research is currently focusing on targeting the neurotransmitters glutamate and gamma-aminobutyric acid to dampen neuronal hyperexcitability.

A central problem in therapeutic application remains the biphasic effect of tetrahydrocannabinol. While low doses can have an anxiolytic effect, higher amounts often lead to an increase in feelings of loss of control and intrusive thoughts. Cannabidiol, on the other hand, is discussed as a more potent starting point due to its modulating effect on serotonin receptors and its anxiolytic properties. The clinical challenge is that chronic consumption can alter receptor density and thus worsen the underlying anxiety and obsessive-compulsive symptoms in the long term, which is why close medical supervision is essential.

• High density of CB1 receptors in the brain circuits relevant to obsessive-compulsive disorder.
• The biphasic effect of THC can lead to an intensification of obsessive thoughts in the event of an overdose.
• CBD has a potentially modulating effect on the serotonin system without psychoactive peaks.
• Risk of tolerance development and receptor downregulation with chronic THC use.

The Swiss legal situation and medical prescribing practice

In Switzerland, the medical use of cannabis has been newly regulated by law since August 2022. Doctors can prescribe corresponding medicinal products directly and without an exceptional licence from the Federal Office of Public Health (FOPH). For the indication of obsessive-compulsive disorder (OCD), however, this prescription is strictly off-label, as no specifically approved finished medicinal products exist for OCD. Medical professionals usually only consider such therapy if established procedures, such as cognitive behavioural therapy and standardised drug treatments, have not shown sufficient success or have caused intolerable side effects.

Patients must also observe the strict legal framework in everyday life. In Swiss road traffic, a strict zero-tolerance policy applies with a limit value of 1.5 micrograms of THC per litre of blood, which severely restricts mobility during THC therapy. As an alternative, those affected often switch to over-the-counter CBD products, whose total THC content must be below one percent in order not to fall under the Narcotics Act. However, these products are not subject to the strict quality controls of medical formulations by Swissmedic, which is why standardised magistral formulations should be preferred for therapeutic purposes.

• Facilitated access to medical cannabis since August 2022 due to the elimination of the FOPH authorisation requirement.
• Prescription for obsessive-compulsive disorder is off-label in cases of proven treatment resistance.
• Strict zero tolerance in road traffic with a THC limit value of 1.5 micrograms per litre of blood.
• Over-the-counter CBD products must have a total THC content of less than one percent.

Therapeutic risks, interactions and treatment alternatives

The combination of cannabinoids with classic drug therapy carries significant risks of pharmacokinetic interactions. High-dose selective serotonin reuptake inhibitors, the standard medication for obsessive-compulsive disorder, are metabolised by the same cytochrome P450 enzymes in the liver as THC and CBD. Concomitant use can unpredictably increase the plasma levels of the antidepressants. This increases the risk of serious side effects such as the potentially life-threatening serotonin syndrome or cardiac arrhythmias. Close monitoring of blood values is therefore mandatory in combination therapy.

Furthermore, cannabis therapy must not hinder the gold-standard psychotherapeutic treatment. Exposure and response prevention is based on patients consciously enduring the emerging anxiety in order to achieve habituation. If this anxiety is artificially dampened by the acute use of cannabis, this can act as a dysfunctional safety behaviour. The therapeutic learning effect of the exposure is thereby blocked, which demonstrably worsens the long-term recovery process. Consequently, cannabinoids should, if at all, only be understood as a supportive option for symptom relief and never as a substitute for active psychotherapy.

• Increased risk of interactions with antidepressants due to the inhibition of CYP450 liver enzymes.
• Risk of blocking the therapeutic success of exposure therapy through emotional dampening.
• Risk of developing psychological dependence in the case of dysfunctional use for coping with anxiety.
• Need for interdisciplinary coordination between treating psychiatrists and general practitioners.

FAQ